Anzeige
Mehr »
Montag, 20.07.2026 - Börsentäglich über 12.000 News
42 Proben im Labor - Jetzt beginnt die spannendste Phase für diese Wolfram-Aktie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4205C | ISIN: CH1476899161 | Ticker-Symbol: J8L0
Frankfurt
20.07.26 | 09:55
1,810 Euro
+6,85 % +0,116
1-Jahres-Chart
VERAXA BIOTECH AG Chart 1 Jahr
5-Tage-Chart
VERAXA BIOTECH AG 5-Tage-Chart

Aktuelle News zur VERAXA BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:06Veraxa Biotech AG: VERAXA Biotech Announces Regulatory Progress with its BiTAC-TCE Development Plan245ZURICH, SWITZERLAND - July 20, 2026 - VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from...
► Artikel lesen
13.07.Veraxa kooperiert mit Ardigen bei KI-gestützter Auswahl von Krebs-Targets5
13.07.Veraxa Biotech AG: VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC Pipeline486Ardigen platform supports VERAXA's in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs)ZURICH, SWITZERLAND...
► Artikel lesen
10.07.VERAXA Biotech names Carl von Halem as interim CFO3
10.07.VERAXA Biotech appoints interim CFO4
VERAXA BIOTECH Aktie jetzt für 0€ handeln
10.07.VERAXA Biotech AG: VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister536ZURICH, SWITZERLAND - July 10, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim...
► Artikel lesen
06.07.Veraxa Biotech AG - 6-K, Report of foreign issuer4
06.07.VERAXA Biotech targets 2028 IND filing for lead candidate6
06.07.VERAXA Biotech AG: VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines342Novel conditionally active T cell engagers sourced from proprietary BiTAC platform are at the basis of advanced partnering initiatives and development activitiesZURICH, SWITZERLAND - July 6, 2026 --...
► Artikel lesen
02.07.Veraxa initiates cell line development for lead cancer therapy5
02.07.VERAXA Biotech AG: VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC-TCE Program370ZURICH, SWITZERLAND - July 02, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for...
► Artikel lesen
25.06.Veraxa stärkt F&E-Kapazitäten in Heidelberg5
24.06.Veraxa Biotech expands Heidelberg lab space4
24.06.VERAXA Biotech AG: VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC-TCE and ADC Programs Advance Towards Clinical Development 477Greater than 60% increase in laboratory space will strengthen R&D capabilities, facilitate acceleration toward clinical development, and increase ability to tap into Heidelberg's world-class medical...
► Artikel lesen
24.06.VERAXA: Nasdaq-Debüt für 1,3 Mrd. US-Dollar24
23.06.XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026317The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026 Aktien 1 CNE100007CW0 Shenzen Xunce Technology...
► Artikel lesen
18.06.Veraxa Biotech Holding AG - 6-K, Report of foreign issuer7
18.06.VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026860BiTAC-ADC in vitro data, along with initial data from the most advanced BiTAC-TCE program recently presented at the American Association for Cancer Research (AACR) Annual Meeting, underpin the Company's...
► Artikel lesen
16.06.Veraxa Biotech Holding AG - 20-F, Annual and transition report of foreign private issuers10
16.06.Heidelberger Biotech VERAXA startet an der Nasdaq mit 1,3 Mrd. Dollar Bewertung43
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1